Elevance Health scores 73 for management and 49 for moat. The management score rests on a return on invested capital of 6.6% and a gross margin of 25.6% — figures that describe a business earning a respectable return on what it employs. Debt sits at 0.76x equity. A moderate moat alongside strong management is a combination worth understanding before the price matters at all.
The price anchors are built on deliberately conservative assumptions. Growth is modelled at 10.3% a year, the rate measured from the filings. The exit multiple assumed is 20.6x. That produces an intrinsic value of $306.43, a 10-CAP price of $304.80 and a payback time price of $389.00, with the value zone set at the highest of the three, $389.00. Today's price of $381.67 sits inside that zone.
The price sits inside the value zone, but the business scores 49 for moat and 73 for management. Cheap and good are different tests, and only one of them is passed here.
| Price | $381.67 |
| Market cap | $82.8B |
| P/E ratio | 17.0x |
| Return on invested capital | 6.6% |
| Gross margin | 25.6% |
| Debt to equity | 0.76x |
| Free cash flow yield | 4.1% |
| Growth rate used | 10.3% |
| Growth rate measured | 10.0% |
| Exit multiple assumed | 20.6x |
| Company | Moat | Buy price |
| The Cigna Group (CI) | 62 | $480.12 |
| CVS Health Corporation (CVS) | 37 | $115.44 |
| Molina Healthcare Inc (MOH) | 39 | $92.07 |
| UnitedHealth Group (UNH) | 43 | $369.90 |
Every number above is built on assumptions that can be changed. In Moatly you can move the growth rate, the exit multiple and the margin of safety and watch every figure recalculate, so you are testing your own view of Elevance Health rather than accepting ours.